Aegis Therapeutics Invited to Present at the Health Care Ventures 2005 Conference
Posted on: Monday, 18 July 2005, 06:00 CDT
Aegis Therapeutics LLC will be presenting at the Health Care Ventures 2005 Conference, sponsored by Dow Jones VentureWire. Dr. Edward T. Maggio, Ph.D., President and Chief Executive Officer, will provide a corporate overview, including a review of the Company's patented Intravail(TM) technology for intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular therapeutics, on Wednesday, Sept. 28 at 9:45 AM at the Sofitel San Francisco Bay, Redwood City, CA.
The conference will include CEOs from 60 companies in the most competitive sectors -- including diabetes, obesity, oncology, neurology, personalized medicine, orthopedics, and eye disorders. Additional information on the conference may be found on the internet at the conference website: http://healthcare-ventures.net/default.asp.
About Aegis Therapeutics
Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail(TM) drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail(TM) also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.
Source: Business Wire
Related Articles
- Preclinical Study Presented at the International Congress of Endocrinology Shows Intravail(R) Drug Delivery Technology Provides Unmatched Non-Invasive Delivery of an Anti-Obesity Peptide
- Aegis Therapeutics Awarded Patent for Its ProTek(R) Room Temperature Stable Human Growth Hormone Formulations Suitable for Metered Nasal Spray Delivery
- Zelos Therapeutics and Aegis Therapeutics Announce Collaboration for Intranasal Delivery of Zelos' ZT-031
- Aegis Therapeutics to Introduce Its Cedar Therapeutics Inc. Spin-Out Company at the Frost and Sullivan Venture Connections 2007 Symposium in San Francisco
- Aegis Therapeutics' ProTek(TM) Formulation Technology Increases Stability and Reduces Immunogenicity of Protein and Peptide Therapeutics
- Aegis Therapeutics Files Second Drug Master File With FDA
- Aegis Therapeutics to Present Intravail(TM) Drug Delivery Technology at CBI's 'Protein Drugs' Conference
- Aegis Therapeutics Files First Drug Master File With the FDA
- Aegis Therapeutics' Intravail(TM) Drug Delivery Technology Gaining Acceptance
 |
 |
User Comments (0)
RSS Feeds